Comparative study of efficacy and safety of intravenous ferric carboxy maltose versus iron sucrose in treatment of postpartum iron deficiency anemia

Suyajna D. Joshi, Shaila Chikkagowdra, Veerendra Kumar CM


Background: Iron deficiency is the commonest treatable cause of postpartum anemia. Parenteral iron therapy results faster and higher replenishment of iron stores and correction of Hb levels with better compliance. The study was to compare the safety and efficacy of ferric carboxy maltose (FCM) with iron sucrose to treat iron deficiency anemia in the post-partum.

Methods: 200 women of postpartum iron deficiency anemia were allocated into two groups. Iron sucrose group, subjects were given I.V. iron sucrose in multiple doses, 200 mg/day on  day 0,2,4,6,8  total of 1000 mg. FCM group , subjects were  given I.V. ferric carboxymaltose 1000 mg single dose.  Both groups Hb%, and serum ferritin were done on 0 and day 30 of last dose of parenteral iron. Side effects, compliance were noted.

Results: There was statistically significant rise (P <0.001) of Hb in FCM group 4.68 g/dl compare to iron sucrose group 3.92 g/dl. Mean rise of serum ferritin was 71.07±27.23 and 95.39±45.84 in iron sucrose and ferric carboxy maltose group. No serious adverse events were reported in either the FCM group or Iron sucrose group.

Conclusions: Properties like ultra-short duration of treatment, fewer adverse reactions and better compliance makes FCM the first-line drug in the management of postpartum iron deficiency anemia.


Ferric carboxy maltose, Iron sucrose, Postpartum anemia, Iron deficiency, Intravenous iron therapy

Full Text:



Atkinson L, Baxley E. Postpartum fatigue. Am Fam Physician. 1994;50(1):113-8.

Bodnar LM, Scanlon KS, Freedman DS, Siega RAM, Cogswell ME. High prevalence of postpartum anemia among low-income women in the United States. Am J Obstet Gynecol. 2001;185(2):438-43.

Aggett P. Iron and women in the reproductive years. In: The British nutrition foundation’s task force, editors. iron: nutritional and physiological significance, 1st edition. London: Chapman and Hall;1995:110-8.

World Health Organization. Reduction of maternal mortality. A joint WHO/UNFPA/UNICEF/World Bank statement. Geneva:WHO;1999.

Bodnar LM, Cogswell ME, Mc Donald. Have we forgotten the significance of postpartum iron deficiency? Am J Obstet Gynecol. 2005;193(1):36-44.

Beard JL, Hendricks MK, Perez EM, Murray KLE, Berg A, Vernon FL et al. Maternal iron deficiency anemia affects postpartum emotions and cognition. J Nutr. 2005;135(2):267-72.

Perez EM, Hendricks MK, Beard JL, Murray KLE, Berg A, Tomlinson M, et al. Mother-infant interactions and infant development are altered by maternal iron deficiency anemia. J Nutr. 2005;135(4):850-5.

Seid MH, Derman RJ, Baker JB, Banach W, Goldberg C, Rogers R. Ferric carboxymaltose injection in the treatment of postpartum iron deficiency anemia: a randomized controlled clinical trial. Am J Obstet Gynecol. 2008;199(4):435-7.

Breymann C, Gliga F, Bejenariu C, Strizhova N. Comparative efficacy and safety of intravenous ferric carboxymaltose in the treatment of postpartum iron deficiency anemia. Int J Gynaecol Obstet. 2008;101(1):67-73.

Pfenniger A, Schuller C, Christoph P, Surbek D. Safety and efficacy of high-dose intravenous iron carboxymaltose vs. iron sucrose for treatment of postpartum anemia. J Perinat Med. 2012;40(4):397-402.

Breymann C. The use of iron sucrose complex for anemia in pregnancy and postpartum period. Semin Hematol. 2006;43(6):28-31.

Seid MH, Mangione A, Valaoras TG, Anthony LB, Barish CF. Safety Profile of Iron Carboxymaltose, a New High Dose Intravenous Iron in Patients with Iron Deficiency Anemia. Blood. 2006;108:3739.

Khandale SN, Kedar K. Managing postpartum anemia with ferric carboxymaltose at tertiary level hospital: a retrospective study. J Evolution Med Dental Sci. 2015;4(44):7580-6.

Verma U, Singh S, Chandra M, Garg R, Singh S. To evaluate the efficacy and safety of single dose intravenous iron carboxymaltose verses multidose iron sucrose in post-partum cases of severe iron deficiency anemia. Int J Reprod Contracept Obstet Gynecol. 2015;4(2):442-6.

Evstatiev R, Marteau P, Iqbal T, Khalif IL, Stein J, Bokemeyer B et al. Fergicor, a randomized controlled trial on ferric carboxymaltose for iron deficiency anemia in inflammatory bowel disease. Gastroenterol. 2011;141(3):846-53.

Calvet X, Ruiz MA, Dosal A, Moreno L, Lopez M, Figuerola A, et al. Cost-minimization analysis favours intravenous ferric carboxymaltose over ferric sucrose for the ambulatory treatment of severe iron deficiency. PLoS One. 2012;7(9):45604.

Gomollon F, Gisbert JP. Current management of iron deficiency anemia in inflammatory bowel diseases: a practical guide. Drugs. 2013;73(16):1761-70.

Khalafallah AA, Dennis AE. Iron deficiency anaemia in pregnancy and postpartum: pathophysiology and effect of oral versus intravenous iron therapy. J Pregnancy. 2012;2012:630519.